[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diffuse-large-b-cell-lymphoma-recurrent\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diffuse-large-b-cell-lymphoma-recurrent":85},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100532193","phase-1-cc-99282--rituximab-early-post-cart-for-non-hodgkins-lymphoma-100532193",false,"NCT06209619","CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma","Early, Risk Adapted CC-99282 + Rituximab Post CAR T-Cell Therapy for Non-Hodgkin's Lymphoma","Inclusion Criteria:\n\n* Written informed consent obtained to participate in the study and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information\n* Age ≥ 18 years at the time of consent\n* Diagnosis of B-cell Non-Hodgkin's lymphoma including either large B-cell lymphoma or follicular lymphoma. Large B-cell subtypes include but are not limited to diffuse large B-cell lymphoma, high grade B-cell lymphoma (except Burkitt's Lymphoma), primary mediastinal B-cell lymphoma, and diffuse large B cell lymphoma transformed from indolent lymphomas\n* Eastern Cooperative Oncology Group (ECOG) Score = 0-2\n* Prior receipt of standard of care CD19 directed CAR-T cell therapy including axicabtagene ciloleucel, tisagenlecleucel, or lisocabtagene maraleucel\n* Pre-CART imaging within 90 days of infusion of CD19.CAR-T for baseline disease evaluation. If patient's receive bridging therapy, imaging evaluation post bridging therapy is encouraged as part of institutional guidelines, but not mandated for inclusion\n* Evidence of objective response on PET\u002FCT at 25-100 days post CD19.CAR-T infusion compared to baseline pre-CART imaging. Objective response in this trial is defined by reduced fludeoxyglucose F-18 (FDG) uptake or reduction in mass size and includes mixed response\n* Evidence of sub-optimal response to CD19.CAR-T as defined in this trial by Deauville Score ≥ 3 on PET\u002FCT at 25-100 days post CD19.CAR-T infusion.\n* Absolute neutrophil count ≥ 7.5 x 10\\^8\u002FL (obtained within 30 days prior to initiating study treatment)\n* Evidence of partial response, though sub-optimal response as determined by persistent MRD positivity. (Example: Deauville Score 1 or 2 is eligible if MRD is positive via clonoseq).\n\n  * Hematological lab values should be without the use of growth factors or transfusion support\n  * Note: Changes in laboratory parameters during the study should not be considered adverse events unless they meet criteria for dose modification(s) of study medication outlined by the protocol and\u002For worsen from baseline during therapy\n* Hemoglobin ≥ 8 x 10\\^9\u002FL (obtained within 30 days prior to initiating study treatment)\n\n  * Hematological lab values should be without the use of growth factors or transfusion support\n  * Note: Changes in laboratory parameters during the study should not be considered adverse events unless they meet criteria for dose modification(s) of study medication outlined by the protocol and\u002For worsen from baseline during therapy\n* Platelets ≥ 50 x 10\\^9\u002FL (obtained within 30 days prior to initiating study treatment)\n\n  * Hematological lab values should be without the use of growth factors or transfusion support\n  * Note: Changes in laboratory parameters during the study should not be considered adverse events unless they meet criteria for dose modification(s) of study medication outlined by the protocol and\u002For worsen from baseline during therapy\n* Estimated glomerular filtration rate (eGFR) (based on chronic kidney disease-epidemiology collaboration \\[CKD-EPI\\] \\* patient's body surface area \\[BSA\\] \\[Du Bois method\\]\u002F1.73m\\^2) ≥ 45 ml\u002Fmin (obtained within 30 days prior to initiating study treatment)\n\n  * Note: Changes in laboratory parameters during the study should not be considered adverse events unless they meet criteria for dose modification(s) of study medication outlined by the protocol and\u002For worsen from baseline during therapy\n* Bilirubin ≤ 1.5 × upper limit of normal (ULN). Subjects with Gilbert's syndrome may be enrolled despite a total bilirubin level \\> 2.0 mg\u002FdL if their conjugated bilirubin is \\\u003C 2.0 × ULN) (obtained within 30 days prior to initiating study treatment)\n\n  * Note: Changes in laboratory parameters during the study should not be considered adverse events unless they meet criteria for dose modification(s) of study medication outlined by the protocol and\u002For worsen from baseline during therapy\n* Aspartate aminotransferase (AST) ≤ 3.0 × ULN (obtained within 30 days prior to initiating study treatment)\n\n  * Note: Changes in laboratory parameters during the study should not be considered adverse events unless they meet criteria for dose modification(s) of study medication outlined by the protocol and\u002For worsen from baseline during therapy\n* Alanine aminotransferase (ALT) ≤ 3.0 × ULN (obtained within 30 days prior to initiating study treatment)\n\n  * Note: Changes in laboratory parameters during the study should not be considered adverse events unless they meet criteria for dose modification(s) of study medication outlined by the protocol and\u002For worsen from baseline during therapy\n* Patients must be able to provide adequate tissue samples for minimal residual disease (MRD) analysis for identification (ID) of baseline tumor deoxyribonucleic acid (DNA). 2 forms of tissue will be acceptable: optional baseline biopsy tissue post CART and prior to initiation of CC-99282, or archival tumor tissue (ex. formalin-fixed paraffin embedded \\[FFPE\\] tumor blocks) from a biopsy containing lymphoma prior to CD19.CART\n* Fridericia's formula-corrected QT interval (QTcF) \\\u003C 470 ms\n* Patients must be able to swallow\u002Fabsorb capsules\n* Females of childbearing potential must have a negative serum pregnancy test within 3 days prior to enrollment. Pregnancy tests must be medically supervised with a minimum sensitivity of 25mIU\u002Fml. NOTE: a female of childbearing potential is a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months, i.e. has had menses at any time in the preceding 24 consecutive months. Documentation of postmenopausal status must be provided. Further information on pregnancy testing and the definition of a female of childbearing potential located in the CC-99282 pregnancy prevention plan document\n* Females of childbearing potential are required to use 2 forms of effective methods of contraception or to agree to practice complete abstinence from the time of informed consent, without interruption, at least 28 days before starting CC-99282, throughout the entire duration of CC-99282, during dose interruptions and for at least 6 months and 2 weeks after the last dose of golcadomide (BMS-986369)\u002FCC-99282. The two contraception methods can be comprised one highly effective method and one additional effective (barrier) method. Further information on acceptable methods is located in the CC-99282 pregnancy prevention plan document\n* Male subjects with female partners must practice complete abstinence or agree to use a condom during sexual contact with a pregnant female or a female of child bearing potential while taking CC-99282, during dose interruptions and for at least 3 months and 2 weeks following the last dose of CC-99282, even if he has undergone a successful vasectomy. Additional information regarding prevention of pregnancy as it pertains to male subjects is contained within the CC-99282 pregnancy prevention plan document\n* Subjects with prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the experimental regimen are eligible for the trial\n* Subject is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study and lactating females must agree to not breastfeed while taking study drugs)\n* Uncontrolled concomitant illness including, but not limited to, symptomatic congestive heart failure (New York Heart Association \\[NYHA\\] class III or IV), unstable angina pectoris, myocardial infarction within 1 month prior to enrollment, uncontrolled cardiac arrhythmias, uncontrolled seizures, or severe non compensated hypertension (Systolic blood pressure \\>= 180mmHg or diastolic blood pressure \\>= 120mmHg)\n* Receipt of CD19.CAR-T for any indication other than that stated within the inclusions criteria\n* Concomitant use of strong CYP3A inhibitors and inducers. Examples include (but are not limited to):\n\n  * CYP3A inhibitors: atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin.\n  * CYP3A inducers: carbamazepine, phenytoin, and rifampin. Patients that are able to come off moderate CYP3A inhibitors\u002Finducers will require a washout period of at least 14 days or 5 half-lives, whichever is shorter, prior to the initiation of study treatment\n* Patients who are actively receiving or have received other investigational agents, including herbal supplements, within 2 weeks or 5 half-lives of enrollment","ALL","18 Years",{"count":19,"type":20},18,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This phase I trial tests the safety, side effects and best dose of CC-99282 with rituximab for the treatment of patients who have received chimeric antigen receptor (CAR) T cell therapy for non-Hodgkins lymphoma and in whom have had a sub-optimal response early on to CAR T-cell therapy. Immunotherapy with CC-99282 may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving CC-99282 with rituximab may be a safe and effective treatment option for patients who have received CAR-T cell therapy for relapsed or refractory non-Hodgkin's lymphoma.",[26,27,28,29,30,31,32,33,34,35,36,37],"B-Cell Non-Hodgkin Lymphoma-Recurrent","Diffuse Large B-Cell Lymphoma-Recurrent","Follicular Lymphoma-Recurrent","High Grade B-Cell Lymphoma-Recurrent","Primary Mediastinal Large B-Cell Lymphoma-Recurrent","Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent","B-Cell Non-Hodgkin Lymphoma-Refractory","Diffuse Large B-Cell Lymphoma-Refractory","Follicular Lymphoma-Refractory","High Grade B-Cell Lymphoma-Refractory","Primary Mediastinal Large B-Cell Lymphoma-Refractory","Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Refractory","RECRUITING","2026-02-24",{"date":41,"type":42},"2026-02-27","ACTUAL",{"date":44,"type":42},"2024-01-29",{"date":46,"type":20},"2026-12-31",{"name":48,"class":49},"Nathan Denlinger","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":21,"phases":60,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":50},"100559923","phase-2-glofitamab-combination-with-chidamide-in-patients-with-recurrentrefractory-dlbcl-100559923","NCT06570447","Glofitamab Combination With Chidamide in Patients With Recurrent\u002FRefractory DLBCL","An Open-label, Single-arm, Single-center, Phase II Clinical Trial of Glofitamab Combination With Chidamide in Patients With Recurrent and Refractory Diffuse Large B-Cell Lymphoma","Inclusion Criteria:\n\n\\- To be eligible for enrollment in this study, a subject must meet all of the following criteria:\n\n1. Signed informed consent\n2. Age ≥ 18 years at the time of informed consent\n3. Patients must be willing and able to comply with protocol-specified hospitalization requirements following administration of Glofitamab. Patients must also be willing to comply with all study-related procedures.\n4. Histologically confirmed DLBCL, including any of the following 2016 WHO Lymphocytes Neoplasm classifications (Swerdlow et al. 2016) Diagnosis: DLBCL-NOS, HGBCL, PMBCL and FL transformed DLBCL (trFL)\n\n   \\- A pathology report (if available) from the initial histopathological diagnosis must be provided. Patients with trFL must also provide a pathology report (if available) at the time of disease transformation. Results of all tissue tests performed at initial diagnosis should be provided, including but not limited to tests to assess cellular origin, BCL2, and MYC abnormalities (if performed).\n5. Patients must have relapsed or Cap following at least two prior lines of systemic therapy (including at least one prior regimen containing anthracene Treatment failure and at least one prior regimen containing anti-CD20 targeted therapy).\n\n   * Patients may have received Autologous haematopoietic stem cell transplant (HSCT) prior to recruitment; consolidative autologous HSCT after Chemotherapy will be counted as a line of therapy.\n   * CAR T cells plus bridging were counted as a treatment line.\n   * Local therapies (e.g., radiotherapy) will not be considered as treatment lines.\n6. Patients must have measurable disease: at least one bidimensionally measurable Lymphadenopathy, defined as \\> 1.5 cm in the longest diameter; or at least one bidimensionally measurable extranodal lesion, defined as \\> 1.0 cm in the longest diameter.\n7. Verify availability of Neoplasm tissues, unless not available per investigator assessment. Freshly collected Biopsy specimens are preferred. Representative Neoplasm tissue specimens or unstained serial sections are acceptable.\n8. Eastern Cooperative Neoplasm Group (ECOG) performance status of 0 or 1\n9. Life expectancy (as assessed by the investigator) ≥ 12 weeks\n10. Carcinoma due to prior anti Adverse event therapy must have resolved to ≤ grade 1 (except Alopecia and Hyporexia).\n11. Adequate liver function\n\n    * Bilirubin total ≤ 1.5 x upper limit of normal (ULN); patients with documented history of Gilbert's syndrome: Bilirubin total ≤ 3 x ULN with elevated indirect Bilirubin;\n    * AST\u002FALT ≤ 3 × ULN\n12. Adequate hematological function:\n\n    * Neutrophil count ≥ 1.5 x 109 cells\u002FL (1.500\u002FμL);\n    * Platelet count ≥ 75,000\u002FμL (and no Platelet transfusion within 14 days before Gpt administration on Day 1 of Cycle 1);\n    * Haemoglobin ≥ 10.0 g\u002FdL (6.2 mmol\u002FL); no Transfusion within 21 days prior to Gpt dosing on Cycle 1 Day 1\n13. Adequate renal function: Serum creatinine ≤ 1.5 × ULN or Creatinine clearance ≥ 50 mL\u002Fmin calculated according to the C OC kroft Gault formula (see Appendix 14) (patients whose renal function is not adequately reflected by Serum creatinine levels as judged by the investigator)\n14. Negative serum Pregnancy test within 7 days prior to study treatment for women of childbearing potential. Amenorrhoea is not required for women of non-childbearing potential who are post-menopausal (≥ 12 months of non-therapeutic Surgery) or Pregnancy test sterilized (absence of ovaries and\u002For uterus). For women of childbearing potential: Agree to remain abstinent (avoid heterosexual intercourse) or to take Contraception measures.\n15. For men: Agree to remain abstinent (avoid heterosexual intercourse) or practice Contraception\n\nExclusion Criteria:\n\nAny subject who meets any of the following criteria should not be enrolled in the study:\n\n1. Inability to comply with protocol-specified hospitalization and restrictions\n2. Richter's transformation\n3. Known active bacterial, viral, fungal, mycobacterial, parasitic, or other Infection (excluding Nail bed infection fungal) at study entry or any major Infection (as evaluated by the investigators) within 4 weeks prior to first study treatment Contacts and Locations\n4. Suspected or Latent tuberculosis disease (confirmed by positive IFNγ release assay)\n5. Positive test result for Chronic hepatitis B virus (HBV) Infection (defined as positive Hepatitis B surface antigen \\[HBsAg\\] serology).\n\n   \\- Patients with occult or previous HBV Infection (defined as HBsAg negative and Hepatitis B core antibody \\[HBcAb\\] positive) may be included if HBV DNA is undetectable, provided they are willing to undergo HBV DNA testing monthly during study treatment (or on Day 1 of each cycle) and monthly for at least 12 months after the last cycle, and are willing to receive appropriate antiviral therapy.\n6. Positive Hepatitis C virus (HCV) Antibody test\n\n   \\- Patients with HCV Polymerase chain reaction are eligible only if the PCR (Antibody positive) is negative for HCV RNA.\n7. Known HIV seropositive status\n\n   \\- For patients with unknown HIV status, HIV testing will be performed at screening if required by local regulations.\n8. Known or suspected chronic active Epstein-Barr Viral infection\n9. Known or suspected history of Haemophagocytic lymphohistiocytosis (H LH)\n10. Pregnancy or lactating, or planning to Pregnancy during treatment and for at least 3 months after the last dose of Gpt or within 2 months after the last dose of Glofitamab\n11. A history of treatment-emergent Immunization related Immunization associated with prior Adverse event treatment agents as follows:\n\n    * Grade 3 Adverse event, except for Grade 3 endocrinopathy managed with alternative therapy\n    * Grade 1-2 Adverse event that did not return to baseline after Therapy cessation\n12. Documented refractory to Obinutuzumab monotherapy\n13. Active autoimmune disease requiring treatment requires investigator assessment of Immunization\n14. Evidence of significant, uncontrolled concomitant disease that could affect adherence to the study protocol or interpretation of results, including Immunization, relevant Lung disorder history (Bronchospasm, Obstruction Pneumopathy), and known autoimmune Diabetes mellitus\n15. History of severe Allergy or Allergic reaction to monoclonal antibody therapy (or recombinant antibody-associated fusion Protein)\n16. History of confirmed progressive multifocal Leukoencephalopathy (PML)\n17. Current or past history of CNS Lymphoma\n18. Current or past history of CNS disease such as Stroke, Epilepsy, CNS Vasculitis, or neurodegenerative disease\n19. Another invasive Neoplasm malignant within the last 2 years (except Basal cell carcinoma and Neoplasm with a low likelihood of recurrence)\n20. Serious or extensive Angina unstable such as New York Heart disorder Association Class III or IV or objectively assessed Class C or D Cardiac disorder, Myocardial infarction within the last 6 months, unstable Arrhythmia, or Cardiovascular disorder\n21. Administration of a live attenuated vaccine within 4 weeks prior to Gpt infusion, or anticipated need for a live attenuated vaccine during the study. ( Note: Flu vaccination should only be administered during the Flu season. Patients must not receive live attenuated Flu vaccine at any time during study treatment.)\n22. Systemic Tumour necrosis agents (including but not limited to Cap Phosphorus amide, thiazolyl Purines, methotrexate, thalidomide, and anti Ammonia factor agents) within 2 weeks prior to Gpt infusions\n\n    * Corticosteroid therapy with ≤ 25 mg\u002Fday prednisone or equivalent is allowed.\n    * Inhaled and topical steroids are allowed.\n23. History of illicit drugs or Alcohol abuse within 12 months prior to screening, as judged by the investigators.\n24. Any other disease, metabolic dysfunction, Physical examination result, or clinical lab result reasonably suspecting a disease or condition that contraindicates the use of an investigational drug\n25. Investigators should review the Vaccination status of potential study patients considered for this study and follow local disease control and prevention guidelines for vaccination of any other non-live vaccinated adults aiming to prevent infectious diseases prior to the study.\n26. Any mental or Cognitive disorder that would limit the understanding, conduct, and compliance with the informed consent form;\n27. Pregnancy or lactating females, or females or male partners planning to Pregnancy during the study;\n28. Other situations that the investigators consider Discomfort to be eligible for this trial",{"count":59,"type":20},22,[61],"PHASE2","An open-label, single-arm, single-center, phase II clinical trial to evaluate the feasibility, efficacy and safety of Glofitamab Combination with chidamide in patients with recurrent\u002Frefractory diffuse large B-cell lymphoma.",[27,33],"2025-03-11",{"date":66,"type":42},"2025-03-13",{"date":68,"type":20},"2025-05-15",{"date":70,"type":20},"2028-12-31",{"name":72,"class":49},"Tianjin Medical University Cancer Institute and Hospital",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":50},"100522713","phase-2-a-rgemox-in-the-treatment-of-early-relapsedrefractory-dlbcl-100522713","NCT06086197","A-RGEMOX in the Treatment of Early Relapsed\u002FRefractory DLBCL","Prospective, Single-center, Phase II Clinical Study of Anlotinib in Combination With Rituximab，Gemcitabine and Oxaliplatin (A-RGEMOX) in the Treatment of Early Relapsed\u002FRefractory Diffuse Large B-cell Lymphoma","Inclusion Criteria:\n\n* Participate in the clinical study voluntarily: fully understand and be informed of the study and sign the informed consent in person; Willing to follow and be able to complete all test procedures.\n* Age≥18 years old, ECOG score ≥2 points, both male and female.\n* Histopathologically confirmed as diffuse large B-cell lymphoma, not otherwise specified; high-grade B-cell lymphoma with MYC and BCL2 and\u002For BCL6 rearrangement; high-grade B-cell lymphoma, not otherwise specified; EBV positive diffuse large B-cell lymphoma\n* Must meet one of the following conditions:\n\n  1. Early relapse: response (≥PR) to first-line systemic therapy (including rituximab and anthracyclines) and disease progression within 12 months after the end of treatment;\n  2. Refractory: first-line treatment includes rituximab and anthracyclines, and no response has been achieved with the most recent systemic treatment (≥PR).\n* At least one evaluable or measurable lesion that meets Lugano2014 criteria (evaluable lesion: PET\u002FCT examination showing increased uptake in lymph nodes or extranodal areas (higher than liver) and PET\u002FCT and\u002For CT consistent with lymphoma; Measurable lesions: nodular lesions \\>15mm in length or extragendal lesions \\>10mm in length with increased FDG uptake).\n* Adequate organ and bone marrow function, no serious hematopoietic dysfunction, abnormal heart, lung, liver, kidney function and immune deficiency:\n\n  1. Neutrophil absolute count (ANC) ≥1.5×109\u002FL (1500\u002Fmm3), platelet ≥75×109\u002FL, hemoglobin ≥100g\u002FL (if bone marrow is involved, platelet ≥50×109\u002FL, ANC ≥1.0×109\u002FL, hemoglobin ≥80g\u002FL).\n  2. Liver function: serum bilirubin ≤2.5 times the upper limit of normal value, aspartate aminotransferase (AST) and alanine aminotransferase (ALT)≤2.5 times the upper limit of normal value (AST or ALT≤5 times the upper limit of normal value is allowed if liver is involved).\n  3. Renal function: creatinine clearance ≥60 mL\u002Fmin (estimated according to the Cockcroft-Gault formula).\n  4. Coagulation function: INR≤1.5 times the upper limit of normal value; PT and APTT≤1.5 times the upper limit of normal value.\n* Left ventricular ejection fraction (LVEF) ≥ 50% in cardiac function examination.\n* Negative serum pregnancy test and effective contraceptive use from signing informed consent until 6 months after the last chemotherapy.\n* Life expectancy \\> 3 months.\n\nExclusion Criteria:\n\n* Pathological subtypes: primary central nervous system diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma.\n* Hemophagocytic syndrome at the time of diagnosis.\n* Central nervous system involvement secondary to lymphoma.\n* Participating in other clinical studies, or the first study drug is administered less than 4 weeks after the end of treatment in the previous clinical study.\n* Medical history of other active malignancy within 2 years prior to enrollment, except for the following conditions:(1) adequately treated in situ of the cervix carcinoma; (2) local basal cell carcinoma or squamous cell carcinoma of skin; (3) Pre-existing malignant disease that is under control and has undergone local radical treatment (surgical or other forms).\n* History of Human Immunodeficiency Virus (HIV) infection and\u002For acquired Immunodeficiency syndrome. Patients with positive hepatitis B surface antigen or hepatitis C virus antibody must be tested hepatitis B virus DNA (no more than 1000 iu\u002Fml) and HCV RNA detection (below the detection limit). Patients with hepatitis B virus carriers, or stabilized hepatitis B with anti-virus treatment and cured hepatitis C can be included.\n* Major surgery was performed within 28 days prior to study initiation.\n* Any active infection, including bacterial, fungal or viral infections, that requires systemic antiinfection therapy within 14 days prior to treatment.\n* Accompanied with severe or uncontrolled disease, including symptomatic of congestive heart failure, uncontrolled hypertension, unstable angina, active peptic ulcer or A history of severe hemorrhagic diseases, such as hemophilia A, hemophilia B, von willebrand disease or blood transfusion or other medical intervention history of spontaneous bleeding.\n* History of stroke or intracranial hemorrhage within 6 months prior to first administration of the study drug.\n* History of deep vein thrombosis (DVT) or pulmonary embolism (PE) within the past 12 months.\n* Patients who must take antiplatelet drugs and anticoagulants at the same time due to underlying diseases, and there is no alternative treatment plan.\n* Continuous treatment with strong CYP1A2 and CYP3A inhibitors or inducers is required. Patients were excluded if they had taken a strong CYP1A2 and CYP3A inhibitors or inducer within 7 days prior to the first administration of the study drug (or had taken these drugs for less than 5 half-lives).\n* Hypersensitivity to the experimental drug is known.\n* Patients deemed unsuitable for the study by researchers.",{"count":81,"type":20},41,[61],"As the most common subtype of lymphoma, diffuse large B-cell lymphoma (DLBCL) is an aggressive but potentially curable malignancy. However, patients with early relapse (relapse within 12 months since diagnosis or the end of first-line treatment, ER) or primary refractory had an even worse prognosis. Thus, the investigators plan to evaluate the efficacy and safety of anlotinib combined with rituximab, gemcitabine, oxaliplatin (A-RGEMOX) in the treatment of early relapsed\u002Frefractory diffuse large B-cell lymphoma.",[85,86],"Diffuse Large B-cell Lymphoma Recurrent","Diffuse Large B Cell Lymphoma Refractory",[88,89,90,91],"angiogenesis","anlotinib","early relapse","treatment","2024-06-23",{"date":94,"type":42},"2024-06-25",{"date":96,"type":42},"2023-10-01",{"date":98,"type":20},"2026-10",{"name":100,"class":49},"Zhejiang Cancer Hospital"]